EnVVeno Medical Corporation (NASDAQ:NVNO) | WebDisclosure

Basculer en Français

9474	Companies
185433	Keywords
117775	Articles
99293	Press releases

Headlines Articles Press releases EnVVeno Medical Corporation

Home
Companies
EnVVeno Medical Corporation

BRIEF

published on 06/17/2024 at 18:05, 1 year 5 months ago

De nouvelles données provisoires sur la guérison de l'ulcère veineux issues de l'essai enVVeno Medical VenoValve seront présentées au VAM2024

EnVVeno Medical VenoValve VAM2024 Ulcère Veineux Essai SAVVE
PRESS RELEASE

published on 06/17/2024 at 18:00, 1 year 5 months ago

New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
enVVeno Medical Corporation to present new interim venous ulcer healing data from VenoValve U.S. trial at VAM2024. Study focuses on treatment of venous disease with innovative bioprosthetic solutions

VenoValve EnVVeno Medical Corporation Venous Disease SAVVE Study Vascular Annual Meeting 2024
BRIEF

published on 05/08/2024 at 20:45, 1 year 6 months ago

EnVVeno Medical Reports Promising First Quarter 2024 Results and Upcoming FDA Filings

Medical Devices Clinical Data EnVVeno Medical Q1 2024 Financial Results VenoValve FDA Approval
BRIEF

published on 05/08/2024 at 20:45, 1 year 6 months ago

EnVVeno Medical publie des résultats prometteurs pour le premier trimestre 2024 et les prochains dépôts auprès de la FDA

EnVVeno Medical Équipement Médical Résultats Financiers Du Premier Trimestre 2024 VenoValve Approbation FDA Donnée Clinique
PRESS RELEASE

published on 05/08/2024 at 20:40, 1 year 6 months ago

enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
enVVeno Medical Corporation reported ending the quarter with $42.9 million cash and investments to fund operations through 2025, presenting positive data at the 46th Annual Charing Cross Symposium

Financial Results EnVVeno Medical Corporation SAVVE Trial Venous Disease VenoValve FDA Approval
BRIEF

published on 04/24/2024 at 12:20, 1 year 7 months ago

Significant Clinical Improvements Reported in enVVeno Medical's VenoValve Pivotal Trial

FDA Approval Clinical Trial VenoValve Charing Cross Symposium Venous Disease
BRIEF

published on 04/24/2024 at 12:20, 1 year 7 months ago

Améliorations cliniques significatives signalées dans l'essai pivot VenoValve d'enVVeno Medical

VenoValve Essai Clinique Approbation De La FDA Symposium De Charing Cross Maladie Veineuse
PRESS RELEASE

published on 04/24/2024 at 12:15, 1 year 7 months ago

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
enVVeno Medical presents positive efficacy data on VenoValve from SAVVE U.S. pivotal trial at Charing Cross International Symposium, showing clinical improvement for severe CVI patients

FDA Approval VenoValve SAVVE Trial CVI Patients Venous Disease
BRIEF

published on 04/16/2024 at 15:05, 1 year 7 months ago

EnVVeno Medical to Present New VenoValve Efficacy Data at Charing Cross Symposium

Clinical Trials EnVVeno Medical VenoValve Chronic Venous Insufficiency Charing Cross Symposium
BRIEF

published on 04/16/2024 at 15:05, 1 year 7 months ago

EnVVeno Medical présentera de nouvelles données sur l'efficacité de VenoValve au symposium de Charing Cross

Essais Cliniques EnVVeno Medical Insuffisance Veineuse Chronique VenoValve Symposium De Charing Cross

Accesswire

Published on 12/05/2025 at 02:35, 7 hours 59 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 8 hours 4 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 9 hours 34 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 11 hours 29 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 11 hours 34 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 10:15, 19 minutes ago

Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 54 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 1 hour 4 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 1 hour 29 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 1 hour 33 minutes ago

Original-Research: DEMIRE AG (von NuWays AG): BUY

Les Echos

Published on 12/05/2025 at 08:45, 1 hour 49 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 1 hour 49 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 1 hour 51 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 16 hours 19 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 16 hours 34 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025

View all LES ECHOS COMFI WIRE